Shares of Crinetics Pharmaceuticals surged in after-hours trading, rising nearly 99.6% after Vertex Pharmaceuticals disclosed a definitive agreement to acquire the San Diego-based company for $85.00 per share in cash. The offer equates to an implied total equity value of about $10.0 billion, or approximately $8.8 billion after accounting for estimated cash on hand.
Both companies' boards of directors have given unanimous approval to the transaction. The parties expect the deal to close in the third quarter of 2026, conditional on regulatory clearances and the approval of Crinetics shareholders.
The strategic case for the acquisition centers on Crinetics' commercial presence and development work in endocrine medicine. Crinetics' lead product, PALSONIFY (paltusotine) - the first and only once-daily oral therapy for adults with acromegaly - was approved by the U.S. Food and Drug Administration in September 2025 and has since received clearance from the European Medicines Agency, establishing an expanding international commercial footprint.
Vertex stated that the combined assets could deliver more than $5 billion in peak annual revenue. The company also said the transaction is expected to be accretive to non-GAAP operating income by 2029. Crinetics' CEO Scott Struthers characterized the agreement as "anchored by a mutual commitment to science and a shared vision for delivering innovative treatments to patient communities that have long been underserved."
The announcement arrived amid a broadly constructive market session: the S&P 500 rose 0.7%, the Nasdaq climbed 1.1%, and the Dow Jones Industrial Average added 0.3% during regular trading. That risk-on backdrop helped amplify investor response to the acquisition news.
Vertex plans to fund the acquisition with a mix of existing cash and debt. The financing package includes $4.5 billion in fully committed bridge financing provided by Bank of America and Morgan Stanley. In the days leading up to the announcement, Crinetics had attracted renewed analyst attention, with UBS initiating coverage and assigning a Buy rating.
Market reaction pushed CRNX shares to trade at $83.91 in after-hours activity - a level that surpassed the stock's prior 52-week high of $57.99 and reflected the market's near-full alignment with the $85.00 offer price.
Contextual takeaways
- The acquisition price and unanimous board approvals removed a degree of uncertainty around the company's path to liquidity for shareholders.
- The regulatory timeline and shareholder vote remain gating items for the transaction to complete in Q3 2026.
- PALSONIFY's FDA approval in September 2025 and recent EMA clearance are central to the commercial rationale cited by Vertex.